Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

Core Insights - Lifecore Biomedical, Inc. reported strong financial results for the fourth quarter and transition period ended December 31, 2025, with revenues of $35.7 million for the fourth quarter, representing a 10% increase year-over-year, and $75.5 million for the transition period, a 20% increase compared to the prior year [4][5][9]. Financial Performance - The company achieved a gross profit margin of 31% during the transition period, up from 26% in the prior year [5][7]. - Operating expenses decreased by 31% to $24.4 million compared to $35.6 million in the previous year [5][8]. - The net loss for the transition period was $18.0 million, an improvement from a net loss of $30.6 million in the prior year [5][9]. - Adjusted EBITDA for the transition period was $13.1 million, significantly higher than $2.6 million in the previous year [5][9]. Strategic Initiatives - Lifecore signed five new programs during the transition period, including three in the fourth quarter, which are expected to drive future growth [4][5][10]. - The company implemented key initiatives aimed at improving EBITDA margins, targeting a mid-term goal of over 25% [10][14]. Future Outlook - For the calendar year 2026, Lifecore expects total revenue to be between $120 million and $125 million, with a projected net loss of $32.9 million to $28.9 million [9][12]. - The company anticipates continued operational progress and disciplined execution, aiming for a 12% revenue CAGR from 2025 to 2029 [14][15]. - Lifecore's strategies include expanding existing customer programs and diversifying its customer base to reduce dependency on any single customer [13][15].